|
|
Post by yossarian on Jan 26, 2016 23:56:19 GMT -5
www.reuters.com/article/us-mannkind-m-a-idUSKCN0V42IRMannkind Corp (MNKD.O), the U.S. maker of inhaled insulin drug Afrezza, is exploring strategic options, including the sale of itself, people familiar with the matter said on Tuesday. Earlier this month, France's Sanofi SA (SASY.PA) and Mannkind terminated an agreement for the development and commercialization of Afrezza. That removed a key source of revenue for Mannkind, and the company's stock has dropped 40 percent since the termination was announced on Jan. 5. It now has a market value of $330 million. Mannkind is working with investment bankers on options, the people said, asking not to be identified because the deliberations are confidential. Mannkind did not respond to requests for comment. Since the termination of the agreement with Sanofi, Mannkind has been developing a new marketing and sales strategy and pursuing other partnerships. It also brought on a new chief executive, Matthew Pfeffer, to replace Alfred Mann, who remains chairman of the board. On Jan. 21, Mannkind entered into a development and commercialization agreement with Receptor Life Sciences, a newly formed private company backed by an undisclosed investor group. It will focus on developing novel inhaled therapeutic products that address such conditions as pain and inflammation. At the J.P. Morgan healthcare conference on Jan. 13, Pfeffer said that despite the loss of the Sanofi agreement, Mannkind has enough cash to operate comfortably until the second half of the year. Alfred Mann, the founder of Mannkind, owns about one-third of the company.
|
|
|
|
Post by trondisc on Jan 27, 2016 0:37:17 GMT -5
5 billion feels like the right number for Afrezza + all of MannKind/Technosphere technologies. Multiple bidders could create a final 10 billion ceiling maximum. Personally I doubt this will go over 10 (ridiculous short interest) and we'll never see 20. My concern is preserving the groundbreaking work that Technosphere has accomplished and building upon a very advanced template with wireless health monitoring. LoL + sad = I guess making my money back is the bonus; I'm very MEH even on good news like today.
There is >>>no way in hell<<< there will be more than two bidders and the outbidding of each other will be quick & short (aka low PPS). In a perfect world it would be Alphabet/Verily. In reality it's Ely Lilly or TEVA. I only wish someone/a company would realize MannKind's true potential. Testimonials from Afrezza users is technology that cannot be ignored. Part of me thinks maybe doing good for the world can succeed; the original reason why I wanted to $upport this company.
This will take several months if not a year to find the right candidate(s). The only way this is taken out instantly (AKA no bidding war) is if a company makes a $20 PPS all or nothing bid and most likely Al Mann will accept and not hear another 3rd party offer per buyout agreement.
|
|
|
|
Post by kc on Jan 27, 2016 0:48:17 GMT -5
5 billion feels like the right number for Afrezza + all of MannKind/Technosphere technologies. Multiple bidders could create a final 10 billion ceiling maximum. Personally I doubt this will go over 10 (ridiculous short interest) and we'll never see 20. My concern is preserving the groundbreaking work that Technosphere has accomplished and building upon a very advanced template with wireless health monitoring. LoL + sad = I guess making my money back is the bonus; I'm very MEH even on good news like today. There is >>>no way in hell<<< there will be more than two bidders and the outbidding of each other will be quick & short (aka low PPS). In a perfect world it would be Alphabet/Verily. In reality it's Ely Lilly or TEVA. I only wish someone/a company would realize MannKind's true potential. Testimonials from Afrezza users is technology that cannot be ignored. Part of me thinks maybe doing good for the world can succeed; the original reason why I wanted to $upport this company. This will take several months if not a year to find the right candidate(s). The only way this is taken out instantly (AKA no bidding war) is if a company makes a $20 PPS all or nothing bid and most likely Al Mann will accept and not hear another 3rd party offer per buyout agreement. I would feel extremely fortunate at $20 PPS.. |
|
|
|
Post by mnkdfann on Jan 27, 2016 0:54:16 GMT -5
|
|
|
|
Post by kball on Jan 27, 2016 3:42:33 GMT -5
5 billion feels like the right number for Afrezza + all of MannKind/Technosphere technologies. Multiple bidders could create a final 10 billion ceiling maximum. Personally I doubt this will go over 10 (ridiculous short interest) and we'll never see 20. My concern is preserving the groundbreaking work that Technosphere has accomplished and building upon a very advanced template with wireless health monitoring. LoL + sad = I guess making my money back is the bonus; I'm very MEH even on good news like today. There is >>>no way in hell<<< there will be more than two bidders and the outbidding of each other will be quick & short (aka low PPS). In a perfect world it would be Alphabet/Verily. In reality it's Ely Lilly or TEVA. I only wish someone/a company would realize MannKind's true potential. Testimonials from Afrezza users is technology that cannot be ignored. Part of me thinks maybe doing good for the world can succeed; the original reason why I wanted to $upport this company. This will take several months if not a year to find the right candidate(s). The only way this is taken out instantly (AKA no bidding war) is if a company makes a $20 PPS all or nothing bid and most likely Al Mann will accept and not hear another 3rd party offer per buyout agreement.
I would feel extremely fortunate at $20 PPS..I would at $3. At $4 i would kiss lepers. |
|
|
|
Post by peppy on Jan 27, 2016 4:25:14 GMT -5
5 billion feels like the right number for Afrezza + all of MannKind/Technosphere technologies. Multiple bidders could create a final 10 billion ceiling maximum. Personally I doubt this will go over 10 (ridiculous short interest) and we'll never see 20. My concern is preserving the groundbreaking work that Technosphere has accomplished and building upon a very advanced template with wireless health monitoring. LoL + sad = I guess making my money back is the bonus; I'm very MEH even on good news like today. There is >>>no way in hell<<< there will be more than two bidders and the outbidding of each other will be quick & short (aka low PPS). In a perfect world it would be Alphabet/Verily. In reality it's Ely Lilly or TEVA. I only wish someone/a company would realize MannKind's true potential. Testimonials from Afrezza users is technology that cannot be ignored. Part of me thinks maybe doing good for the world can succeed; the original reason why I wanted to $upport this company. This will take several months if not a year to find the right candidate(s). The only way this is taken out instantly (AKA no bidding war) is if a company makes a $20 PPS all or nothing bid and most likely Al Mann will accept and not hear another 3rd party offer per buyout agreement. I would feel extremely fortunate at $20 PPS.. So a while back I looked at TEVA. Shares Outstanding5: 852.00M
Float: 828.18M Stock price $64.00 1 teva for 10 mnkd. 6.40 a share. teva shares outstanding 900 ish million. Valuation MNKD 3.1 billion. ( if, this illustration)
TEVA Market Cap (intraday)5: 54.58B finance.yahoo.com/q/ks?s=teva&ql=1
Doesn't teva have the migraine injectable?
Added: on the wild inappropriate speculation side of me. wouldn't a bidding war be an interesting aside of all this. For wild speculation instance, regeneron becomes interested in the delivery system. I have been flashing the technosphere patent for nodal delivery. Right up regenerons sleeve of potential beneficiary patents to own. Being that sanofi returned MNKD, that would be twisted and ironic to be sucked up by regeneron.
|
|
|
|
Post by liane on Jan 27, 2016 5:40:41 GMT -5
Locking this thread; we already have one going.
|
|
